169273-94-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-(N-benzyloxycarbonyl)-p-methoxyphenylglycine is used as a pharmaceutical intermediate for the synthesis of various drugs and bioactive compounds. Its unique structure allows for the development of new medications targeting pain, inflammation, and neurological disorders.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-(N-benzyloxycarbonyl)-p-methoxyphenylglycine is used as a versatile building block for the synthesis of diverse molecules. Its structural components, including the benzyl, oxycarbonyl, and methoxyphenyl groups, enable the creation of a broad spectrum of compounds with potential applications in healthcare and pharmaceuticals.

Upstream product

• 2540-53-6 2-(4-methoxyphenyl)glycine 
• 104-01-8 4-Methoxyphenylacetic acid 
• 501-53-1 benzyl chloroformate 
• 169176-61-8 (2S,4S)-3-<2-Azido-2-(4-methoxyphenyl)-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 
• 143589-97-3 (4S)-3-<2-(4-Methoxyphenyl)-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 
• 126702-34-9 C₁₄H₁₈O₄ 
• 394210-44-7 4-(4-methoxy-phenyl)-2,5-dioxo-oxazolidine-3-carboxylic acid benzyl ester 
• 170689-03-9 N-(benzyloxycarbonyloxy)succinamide 
• 24593-48-4 (2S)-2-amino-2-(4-methoxyphenyl)acetic acid 
• 169176-62-9 (2S,4S)-3-<2-<<(Phenylmethoxy)carbonyl>amino>-2-(4-methoxyphenyl)-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 

Downstream Products

• 169176-57-2 N--L-(4-methoxyphenyl)glycinyl>-D-(3-hydroxy-4-methoxyphenyl)glycine ethyl ester 
• 96155-89-4 L-p-methoxyphenylglycine amide 
• 170688-57-0 2-amino-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide 
• 170688-61-6 (S)-α-amino-4-methoxy-N-methyl-N-phenylbenzeneacetamide 
• 170688-60-5 (S)-α-amino-4-methoxy-N-phenylbenzeneacetamide 
• 170688-65-0 (S)-α-Amino-4-methoxy-N-(phenylmethyl)benzeneacetamide 
• 170688-75-2 (S)-2-Amino-2-(4-methoxy-phenyl)-1-piperidin-1-yl-ethanone 
• 170688-73-0 2-amino-N-cyclohexyl-2-(4-methoxy-phenyl)-acetamide 
• 170688-59-2 2-[2-(4-benzyloxy-3-methanesulfonylamino-phenyl)-2-hydroxy-ethylamino]-N-tert-butyl-2-(4-methoxy-phenyl)-acetamide 

Relevant academic research and scientific papers

Catecholamine surrogates useful as β3 agonists

Compounds of the formula STR1 or pharmaceutically acceptable salts thereof wherein: A is a bond, --(CH 2) n -- or --CH(B)--, where n is an integer of 1 to 3 and B is --CN, --CON(R 9)R 9'' or --CO 2 R 7 ;R 1 is lower alkyl, aryl or arylalkyl;R 2 is hydrogen, hydroxy, alkoxy, --CH 2 OH, cyano, --C(O)OR 7, --CO 2 H, --CONH 2, tetrazole, --CH 2 NH 2 or halogen; STR2 R 3 is hydrogen, alkyl, heterocycle or R 4 is hydrogen, alkyl or B;R 5, R 5'', R 8, R 8'' or R 8"" are independently hydrogen, alkoxy, lower alkyl, halogen, --OH, --CN, --(CH 2) n NR 6 COR 7, --CON(R 6)R 6'', --CON(R 6)OR 6'', --CO 2 R 6, --SR 7, --SOR 7, --SO 2 R 7, --N(R 6)SO 2 R 1, --N(R 6)R 6'', --NR 6 COR 7, --OCH 2 CON(R 6)R 6'', --OCH 2 CO 2 R 7 or aryl; orR 5 and R 5'' or R 8 and R 8'' may together with the carbon atoms to which they are attached form an aryl or heterocycle;R 6 and R 6'' are independently hydrogen or lower alkyl; andR 7 is lower alkyl;R 9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R 9 and R 9'' may together with the nitrogen atom to which they are attached form a heterocycle; with the proviso that when A is a bond or --(CH 2) n and R 3 is hydrogen or unsubstituted alkyl, then R 4 is B or substituted alkyl. These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.

Synthesis of a 16-Membered Cyclic Peptide Model of the BCF Rings of Ristocetin A Using Arene-Ruthenium Chemistry Coupled with Cycloamidation

A convergent synthetic approach to the cyclic peptide 4, which is a model for the B/C/F ring system of ristocetin B, is described.A key reaction is the coupling of the phenolic dipeptide 5, constructed from arylglycine subunits, with the chlorophenylalanine-RuCp cationic complex 6, followed by demetalation of the product to give the diaryl ether 7, without epimerization at any of the amino acid residues.Deprotection of 7 followed by cycloamidation affords the target molecule 4, produced as a mixture of atropdiastereomers which were separated and characterized by NMR spectroscopy.